Ascendant Dx Closes on $2M Financing to Develop Proteomic-based Breast Cancer Test | GenomeWeb

NEW YORK (GenomeWeb) – Proteomics-based diagnostics firm Ascendant Dx today said that it closed on a $2 million funding round, which will support clinical trials for and commercialization of its tears-based breast cancer detection test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.